Preclinical development of molecular-targeted agents for cancer.
about
Early phase clinical trials to identify optimal dosing and safetyStimulated Raman scattering microscopy: an emerging tool for drug discoveryPrioritizing therapeutic targets using patient-derived xenograft modelsEnhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case studyEvaluation by quantitative image analysis of anticancer drug activity on multicellular spheroids grown in 3D matricesBioactivity-guided identification and cell signaling technology to delineate the lactate dehydrogenase A inhibition effects of Spatholobus suberectus on breast cancerMultiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitorCulture conditions tailored to the cell of origin are critical for maintaining native properties and tumorigenicity of glioma cells.Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtainedDrug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.Assessing the efficacy of molecularly targeted agents on cell line-based platforms by using system identification.Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testingDevelopment of a realistic in vivo bone metastasis model of human renal cell carcinomaSingle-cell measurement of the uptake, intratumoral distribution and cell cycle effects of cisplatin using mass cytometry.In silico model-based inference: an emerging approach for inverse problems in engineering better medicinesEmerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy.Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screeningA validated tumorgraft model reveals activity of dovitinib against renal cell carcinomaNew cast for a new era: preclinical cancer drug development revisited.An imaging-based platform for high-content, quantitative evaluation of therapeutic response in 3D tumour modelsPARP-1 may be involved in angiogenesis in epithelial ovarian cancer.Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactorDiscovery of small molecule cancer drugs: successes, challenges and opportunities.Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors.Safety and feasibility of targeted agent combinations in solid tumours.Translating metastasis-related biomarkers to the clinic--progress and pitfalls.Appraising iniparib, the PARP inhibitor that never was--what must we learn?Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.Three-dimensional cell culture models for anticancer drug screening: Worth the effort?Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs.Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer.Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?Functional exploration of colorectal cancer genomes using Drosophila.The production of 3D tumor spheroids for cancer drug discovery.Drugs for solid cancer: the productivity crisis prompts a rethink.Neutrophils in cancer: prognostic role and therapeutic strategies.Culture conditions defining glioblastoma cells behavior: what is the impact for novel discoveries?Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts.The latest animal models of ovarian cancer for novel drug discovery.
P2860
Q26865076-C148C20B-645C-4B7D-BAFD-5EA63A4D6861Q28067096-BBB2079F-8DEE-4093-9BCE-92C52EE0A100Q28083993-68E83D8A-645B-49F9-AAC0-390E970C5FF1Q28084489-7E188C88-130F-4BD8-84DC-59BC2055FBD1Q28468379-68D6D6E2-8D94-4ABB-B67E-575536A48CBCQ28486165-03DC8381-9525-4625-B446-497C57736C54Q28728165-3DC271F9-2DB6-421C-92AE-2DAA53E361E8Q30276928-61CB77C8-0AAB-460A-B3A5-20A1B5C25F14Q30582030-CA57B7F2-61DE-4105-92C4-DCF144C21C5EQ31036196-FF45E33E-C4EC-4532-BF88-BCE3AF657440Q34263870-A1B56CB3-481E-497E-B02E-C77F70F832A5Q34470371-548D5E4C-5B5A-4D15-9C65-A786CD2D6D54Q35041892-33CB1D3C-490C-4579-B443-B1257BB44F0FQ35154534-D22E6BFE-BA1A-4CC7-A78F-FB0C305A8CC5Q35209694-F04D19D1-A6E2-4F77-8949-CF4AC42996E8Q35984945-E1E59F1F-D149-40ED-B710-CDFA548300EEQ36111593-EFF9AD0B-CB4B-4264-ADE1-0C8137D7345CQ36356303-506B241E-990B-4D5A-8BC2-0460F824A615Q36606040-7E0424A5-2AB6-478D-8861-8E7524C61D7BQ37123902-909236A6-AEC1-4FE9-9D0E-8F4423066095Q37489267-3E3DD2F3-04C6-41B8-BC78-90874A6DB1E4Q37581637-722519AB-975B-4150-B163-B2DE8BE2E060Q37686102-8623D290-B6DD-467E-9A6A-027E9359FE5CQ37996113-2E6A5FBC-616C-4D56-A8C0-72DE76FDEE90Q38028795-9CC30BDB-F0EA-4AFB-AA0C-9EC8B0506684Q38077440-F645FB94-3669-4AE9-B2AE-41DB874B2B85Q38079125-7B8F6FD0-52DD-4904-B448-B0F8C515C2A3Q38152942-0443E4B6-727F-4671-BABC-17F609BDA376Q38171330-E5198142-B60D-4808-B931-86E6E8021EC4Q38724273-18D99F58-B294-4218-AD9F-EF3FFCB71100Q38752180-533BF694-75A7-44B9-B6EC-BBC370D48CBBQ38794482-F30C4AF4-0B41-437C-95A8-F1877E372038Q38969204-8A4280E7-92DC-4765-864F-E84B160C3AE3Q39145987-7F0F5B2F-E641-4471-909B-252BCC575D91Q39396046-D4DAD9FA-ADCC-4F6F-917A-00A5E2E526EBQ41313977-E1AB8648-64E1-4FD0-A142-41CD3A41C0F9Q41431390-0FB52619-E8D0-453A-A296-3CD0B9EDE65AQ42366669-F2762EDB-ADBD-42E2-9473-DC52FF9A15E7Q47204651-7A798232-F50E-4306-A376-FD87405F8D33Q47553013-06A0CAE4-8EB9-4E63-8E0B-E23529B99865
P2860
Preclinical development of molecular-targeted agents for cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Preclinical development of molecular-targeted agents for cancer.
@en
Preclinical development of molecular-targeted agents for cancer.
@nl
type
label
Preclinical development of molecular-targeted agents for cancer.
@en
Preclinical development of molecular-targeted agents for cancer.
@nl
prefLabel
Preclinical development of molecular-targeted agents for cancer.
@en
Preclinical development of molecular-targeted agents for cancer.
@nl
P2093
P2860
P1476
Preclinical development of molecular-targeted agents for cancer.
@en
P2093
Atanasio Pandiella
Ian F Tannock
Lillian L Siu
P2860
P304
P356
10.1038/NRCLINONC.2010.194
P407
P577
2010-12-07T00:00:00Z